Cell Therapies Move Forward in Type 1 Diabetes Clinical Trials

Cell therapies for Type 1 diabetes represent a different approach than current insulin treatments. Instead of replacing insulin from the outside, these therapies aim to restore the body's own insulin-producing capacity by transplanting healthy islet cells—the cells in the pancreas that naturally produce insulin.

The cells used in these therapies can come from several sources: donor pancreases (allogeneic islets), or laboratory-grown cells derived from stem cells or pluripotent stem cells. Some therapies involve genetic editing to make donor cells less likely to be rejected by the immune system.

One patient in a Chinese clinical trial achieved sustained insulin independence 75 days after receiving chemically induced pluripotent stem-cell-derived islets transplanted under the abdominal muscle. At one year, the patient's blood sugar remained well-controlled without external insulin, with their glycated hemoglobin (a measure of long-term blood sugar control) at around 5%—a non-diabetic level.

In Vertex's Zimislecel trial, participants receiving a full dose showed promising safety and efficacy outcomes through 12 months. Some participants achieved freedom from severe low blood sugar episodes while maintaining good overall blood sugar control.

In a groundbreaking small study, a patient who received genetically modified donor islet cells and received no immunosuppressive drugs showed stable, glucose-responsive insulin secretion at 12 weeks with no serious adverse events.

Lantidra, an FDA-approved donor-derived islet therapy, is now available to some patients. Vertex's Zimislecel is in phase 1/2/3 clinical trials. Both represent first-generation cell therapies that show promise, but they have limitations that researchers are actively addressing.

Current challenges include ensuring transplanted cells survive in the body long-term, maintaining consistent insulin production, protecting cells from immune rejection, and scaling up manufacturing to produce enough cells for broader use. All patients currently receiving these therapies require some form of immunosuppressive medication to prevent their immune system from attacking the transplanted cells.

Breakthrough T1D's Project ACT (Accelerate Cell Therapies) is working to advance the field by supporting research at the preclinical, clinical, and manufacturing levels. The organization notes that multiple new cell therapies are in the clinical pipeline working toward regulatory approval.

The ultimate goal is to develop manufactured islet therapies that are available in large supply, survive and function in the body after transplantation, and remain protected from immune rejection without requiring lifelong immunosuppressive therapy. Recent work using genetic editing—such as CRISPR technology—shows early promise for this vision of reduced or eliminated immunosuppression.

Beyond cell therapies themselves, researchers and advocates are also working on the regulatory and insurance pathways to ensure that approved therapies can reach patients who need them.

These developments are significant because they represent a fundamentally different treatment approach. However, it's important to understand where these therapies stand: they are investigational treatments in clinical trials, not yet widely available, and still require careful medical oversight.

If you're interested in learning more about cell therapy trials or exploring whether you might be eligible to participate, speak with your diabetes care team. Clinical trials are recruiting at specialized medical centers, and information about ongoing studies is available through ClinicalTrials.gov and organizations like Breakthrough T1D.

Origin: breakthrought1d.org (News report). Evidence: News report, corroborated with 4 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.